The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).
 
Aly-Khan A. Lalani
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Merck; Novartis; Pfizer; Roche/Genentech; Tersera
Consulting or Advisory Role - Abbvie; Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Merck; Pfizer; Roche/Genentech; Tersera
Research Funding - BioCanRx (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Ipsen (Inst); Novartis (Inst); Roche (Inst)
 
Anand Swaminath
No Relationships to Disclose
 
Gregory Russell Pond
Employment - Roche Canada (I)
Stock and Other Ownership Interests - Roche Canada (I)
Honoraria - AstraZeneca; AstraZeneca
Consulting or Advisory Role - Merck; Profound Medical; Takeda
 
Scott C. Morgan
Consulting or Advisory Role - Astellas Pharma; Bayer; Janssen; Tersera
 
Arun Azad
Honoraria - Aculeus Therapeutics; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Serono; Merck Sharp & Dohme; Novartis; Noxopharm; Pfizer; Sanofi; Telix Pharmaceuticals; Tolmar
Consulting or Advisory Role - Aculeus Therapeutics; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Serono; Merck Sharp & Dohme; Novartis; Noxopharm; Pfizer; Sanofi; Telix Pharmaceuticals; Tolmar
Speakers' Bureau - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Serono; Novartis
Research Funding - Aptevo Therapeutics (Inst); Astellas Pharma; Astellas Pharma (Inst); AstraZeneca; AstraZeneca (Inst); Bionomics (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Hinova Pharmaceuticals (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); MedImmune (Inst); Merck Serono; Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Synthorx (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Janssen; Merck Serono; Pfizer; Sanofi; Tolmar
 
William Chu
No Relationships to Disclose
 
Anil Kapoor
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Eisai; Ipsen; Janssen Oncology; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst)
 
Michael Bonert
No Relationships to Disclose
 
Jonathan L. Bramson
No Relationships to Disclose
 
Michael G. Surette
No Relationships to Disclose
 
Dominick Bosse
Honoraria - Amgen; AstraZeneca; Bayer; BMS; Eisai; Ipsen; Janssen; Merck; Pfizer
Consulting or Advisory Role - Abbvie; AstraZeneca Canada; Bayer; Bristol-Myers Squibb; Ipsen; Merck; Merck; Pfizer
Travel, Accommodations, Expenses - ipsen
 
Shankar Siva
Honoraria - AstraZeneca; Bristol Meyer Squibb (Inst); Bristol Meyer Squibb (Inst); Roche (Inst); Varian Medical Systems (Inst)
Consulting or Advisory Role - AstraZeneca; Janssen (Inst)
Research Funding - Bayer (Inst)
Travel, Accommodations, Expenses - AstraZeneca (Inst)
 
Georg A. Bjarnason
No Relationships to Disclose
 
Darin Gopaul
No Relationships to Disclose
 
Naveen S. Basappa
Stock and Other Ownership Interests - illumiSonics
Honoraria - Astellas Pharma; Eisai; Ipsen; Janssen; Merck; Pfizer
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; EMD Serono; Ipsen; Janssen; Merck; Pfizer; Roche Canada
Travel, Accommodations, Expenses - Eisai; Janssen
 
Jim Wright
No Relationships to Disclose
 
Sebastien J. Hotte
Honoraria - Astellas Scientific and Medical Affairs Inc; Bayer; Eisai; Ipsen; Janssen Oncology; Merck
Consulting or Advisory Role - Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Merck; Pfizer; Seagen
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Ayala Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Janssen Oncology (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); SignalChem (Inst)
Travel, Accommodations, Expenses - Eisai